Log in with your email address username.


[Comment] The switch to infliximab biosimilars

In The Lancet, Kristin Jørgensen and colleagues1 report results from the NOR-SWITCH study, the first randomised non-inferiority trial of infliximab, showing that switching from originator to biosimilar does not lead to disease worsening, compromised safety, or increased immunogenicity in a group of patients in all the authorised therapeutic indications. In this 52-week phase 4 trial, 482 adult patients on stable treatment with infliximab originator were randomly assigned to either continued originator or switch to infliximab biosimilar treatment (CT-P13), using an unchanged dosing regimen.